Avoid the stress of overpaying for a stock or missing an opportunity by using the right tools and insights to evaluate Kamada Ltd. before investing.

In this article, we go over a few key elements for understanding Kamada Ltd.’s stock price such as:

• Kamada Ltd.’s current stock price and volume
• Why Kamada Ltd.’s stock price changed recently
• Upgrades and downgrades for KMDA from analysts
• KMDA’s stock price momentum as measured by its relative strength

About Kamada Ltd. (KMDA)

Before we jump into Kamada Ltd.’s stock price, history, target price and what caused it to recently rise, let’s take a look at some background.

Kamada Ltd. manufactures and sells plasma-derived protein therapeutics. Its products include KAMRAB/KEDRAB indicated as prophylaxis of rabies; CYTOGAM for prophylaxis of Cytomegalovirus disease in kidney, lung, liver, pancreas, heart, and heart/lung transplants; VARIZIG for post exposure prophylaxis of varicella; WINRHO SDF for immune thrombocytopenic purpura and suppression of rhesus isoimmunization; HEPAGAM B for prevention of hepatitis B recurrence liver transplants and post-exposure prophylaxis; GLASSIA for intravenous AATD; KAMRHO (D) IM for prophylaxis of hemolytic disease of newborns; and Echis coloratus and Vipera palaestinae Antiserum to treat snake bite. The company also distributes biopharmaceutical products in Israel, including BRAMITOB to manage chronic pulmonary infection; FOSTER to treat asthma; TRIMBOW for chronic obstructive pulmonary disease; PROVOCHOLINE for the diagnosis of bronchial airway hyperactivity; AEROBIKA, an OPEP device; RUPAFIN and RUPAFIN ORAL SOLUTION for allergic rhinitis and Urticaria; SINTREDIUS for rheumatoid arthritis, systemic lupus erythematosus, and mild-moderate juvenile dermatomyositis; IVIG for various immunodeficiency-related conditions; VARITECT for chicken pox and zoster herpes; ZUTECTRA and HEPATECT CP for prevention of hepatitis B; MEGALOTECT CP for CMV virus; RUCONEST for angioedema attack; HEPARIN SODIUM INJECTION for thrombo-embolic disorders and prophylaxis of deep vein thrombosis and thromboembolic events; ALBUMIN and ALBUMIN for blood plasma; Factor VIII for hemophilia type A; and Factor IX for hemophilia type B. In addition, it distributes COAGADEX to treat hereditary factor X deficiency; IXIARO for Japanese encephalitis; VIVOTIF for salmonella typhi; PROCYSBI for nephropathic cystinosis; LAMZEDE for alpha-mannosidosis; RYPLAZIM for hypoplasminogenemia; ELIGARD for prostate cancer; and BEVACIZUMAB KAMADA for various cancers. The company was incorporated in 1990 and is headquartered in Rehovot, Israel.

Want to learn more about Kamada Ltd.’s stock? Click the button below to subscribe to A+ Investor and get access to everything you need to know about Kamada Ltd..

Kamada Ltd.’s Stock Price as of Market Close

As of July 31, 2026, 4:00 PM, CST, Kamada Ltd.’s stock price was $7.140.

Kamada Ltd. is up 0.56% from its previous closing price of $7.100.

During the last market session, Kamada Ltd.’s stock traded between $7.111 and $7.250. Currently, there are approximately 59.03 million shares outstanding for Kamada Ltd..

Kamada Ltd.’s price-earnings (P/E) ratio is currently at 20.5, which is high compared to the Biotechnology industry median of 19. The price-earnings ratio gauges market expectation of future performance by relating a stock’s current share price to its earnings per share.

Kamada Ltd. Stock Price History

Kamada Ltd.’s (KMDA) price is currently down 2.72% so far this month.

During the month of July, Kamada Ltd.’s stock price has reached a high of $7.710 and a low of $6.890.

Over the last year, Kamada Ltd. has hit prices as high as $9.350 and as low as $6.500. Year to date, Kamada Ltd.’s stock is up 1.13%.

Sign Up to Receive a Free Special Report Showing How A+ Grades Can Help You Make Smarter Investment Decisions

What Caused Kamada Ltd. Stock’s Price to Rise?

Stock prices are primarily based on seller supply and buyer demand. But have you ever wondered about what other factors affect a stock's price?

When an analyst changes their opinion of a stock by upgrading or downgrading their rating, it often leads to a sudden stock price adjustment. As of July 31, 2026, there was 1 analyst who downgraded Kamada Ltd.’s stock and 1 analyst who upgraded over the last month.

Additionally, you'll want to evaluate Kamada Ltd.’s financial health and valuation. Investors can use AAII's Value Grade, which combines six key valuation metrics like P/E and P/S ratios for a comprehensive analysis to conduct analysis on Kamada Ltd.’s valuation and financial health. This approach mitigates the limitations of single-metric evaluations.

Kamada Ltd.’s current valuation based on AAII’s Value Grade is a D, which means it is considered to be Expensive.

Learn how to evaluate stocks with AAII Grades and Scores with A+ Investor today.

Lastly, news and media coverage as well as recent press reports about the company or its industry may cause stock prices to fluctuate. You can check out the most recent news articles about Kamada Ltd. (KMDA) by visiting AAII Stock Evaluator.

Relative Price Strength of Kamada Ltd.

Relative price strength measures a stock's performance against the market, helping investors identify stocks that are outperforming benchmarks.

For AAII’s Momentum Grade, a weighted relative price strength is calculated. Follow this link to learn more about the Momentum Grade.

As of July 31, 2026, Kamada Ltd. has a weighted four-quarter relative price strength of -6.38%, which translates to a Momentum Score of 32 and is considered to be Weak.

Want to learn more about how Kamada Ltd. is graded based on AAII’s composite scores for value, growth, quality and earnings estimate revisions? Subscribe to A+ Investor today.

Kamada Ltd. Stock Price: Bottom Line

As of July 31, 2026, Kamada Ltd.’s stock price is $7.140, which is up 0.56% from its previous closing price.

AAII advises against making stock decisions based solely on price or past returns. Instead, consider a variety of metrics, fundamentals, and analytics to evaluate a stock like Kamada Ltd. stock prices are influenced by market supply and demand and offer just a snapshot of a company's overall health.

Subscribing to AAII's A+ Investor provides access to comprehensive analytics and insights for confident investing.